Myosana Therapeutics

Myosana Therapeutics was founded in 2018 by Nick Whitehead and Stan Froehner, professors at the University of Washington School of Medicine. The company is dedicated to developing new gene therapies to slow skeletal muscle degeneration and heart failure in patients, thereby improving their quality of life, extending lifespan, and reducing the disease burden of Duchenne Muscular Dystrophy (DMD) and other neuromuscular disorders.